Global Telmisartan Tablet Market Research Report 2022

Telmisartan oral tablet is used to treat high blood pressure. 
Due to the COVID-19 pandemic, the global Telmisartan Tablet market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Telmisartan Tablet market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Telmisartan Tablet landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
20mg/pill accounting for % of the Telmisartan Tablet global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Telmisartan Tablet include Boehringer Ingelheim, Glenmark, Hikma, Solco Healthcare, Torrent, Zydus, Alembic, Amneal Pharmaceuticals and Aurobindo, etc. In terms of revenue, the global 3 largest players have a % market share of Telmisartan Tablet in 2021.
This report focuses on Telmisartan Tablet volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Telmisartan Tablet market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Telmisartan Tablet Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
20mg/pill
40mg/pill
80mg/pill
Segment by Application
Hospital
Special Clinic
Recovery Center
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Boehringer Ingelheim
Glenmark
Hikma
Solco Healthcare
Torrent
Zydus
Alembic
Amneal Pharmaceuticals
Aurobindo
Cadista
Sandoz
Camber Pharmaceuticals